Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
New HIV therapy reduces virus, boosts immunity in drug-resistant patients

Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

Published
16 August 2018
From
Science Daily
Reported 'PrEP Failure' in Thailand May Be a Missed Acute HIV Infection: Here's What You Need to Know

The Infectious Diseases Society of America reported on June 29, 2018, that a new HIV acquisition had been found in a person using pre-exposure prophylaxis (PrEP). According to the journal article, a 28-year-old cisgender male in Thailand began using PrEP on March 16, 2016, after being verified HIV negative by a third generation antibody test. However the third generation antibody test available in this case has a window period of three to 12 weeks, with 3% of the population still testing HIV negative after 12 weeks. This is why clinical testing sites use RNA testing whenever possible, as the RNA test from May 13 did show positive for HIV while the third generation antibody test on the same day showed HIV negative.

Published
17 July 2018
From
TheBody PRO
Low CD4 count in patients with HIV prolongs influenza viral shedding

HIV-infected individuals with a low CD4 count experienced a longer duration of influenza virus shedding, according to findings published in The Journal of Infectious Diseases.

Published
11 June 2018
From
Healio itj+ (requires free registration)
Computer Models Are Changing How We Craft HIV-AIDS Policies

A computer modeling of AIDS-affected populations of sub-Saharan Africa has recently enabled the World Health Organization (WHO) to identify a cost-effective measure to address the increasing prevalence of drug-resistant HIV in the region.

Published
04 May 2018
From
Healthcare Analytics News
World Health Organization Debunks Reports of New HIV Strain

Respected world agencies are downplaying initial reports of a new strain of HIV found in the Philippines. The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) have both released statements that soundly reject recent initial media reports that warned their readers of a new, untreatable strain of HIV that has been identified in certain areas.

Published
13 April 2018
From
HIV Plus
ARV stock-outs kill more Ugandans

“Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

Published
12 April 2018
From
The Observer
Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence

When is a pre-exposure prophylaxis (PrEP) failure actually a provider failure? And how do we tell the difference? This was a question that came up at CROI 2018 after a poster presentation titled "Seroconversion on PrEP: A Protocol for Untangling Adherence versus Resistance Failure" sparked conversations and debates about how you distinguish an example of tenofovir/emtricitabine (Truvada) failing to protect an individual from acquiring HIV, versus a provider whose negligence and failure to follow Centers for Disease Control and Prevention (CDC) protocol may have put his or her patient at grave risk.

Published
21 March 2018
From
The Body PRO
Statement of UNAIDS on news reports of a new HIV strain in the Philippines

UNAIDS is concerned that media reports which make reference to HIV research in the Philippines are being interpreted as saying that there is a new and untreatable strain of the virus in the country. There is no new strain of HIV which has been found in the Philippines.

Published
21 March 2018
From
UNAIDS Asia-Pacific
FDA approves new HIV treatment for patients who have limited treatment options

Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

Published
07 March 2018
From
FDA
Infectious diseases doctor sounds an international alarm about HIV treatment resistance in the Philippines

Dr. Edsel Salvana explains the global implications of treatment-resistant HIV in the Philippines.

Published
25 January 2018
From
Science Speaks
← First12345...9Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.